Evidence map›Paper›PMID 26808421›Full record

ArticlePloS one2016

Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.

María José Ferri, Marc Saez, Joan Figueras, Esther Fort, Miriam Sabat, Santiago López-Ben, Rafael de Llorens, Rosa Núria Aleixandre, Rosa Peracaula

Open access · goldAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

María José FerriClinic Laboratory, Dr. Josep Trueta University Hospital, Girona, Spain.
Marc SaezResearch Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain.
Joan FiguerasHepato-biliary and Pancreatic Surgery Unit, Dr. Josep Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
Esther FortGastroenterology Unit, Dr. Josep Trueta University Hospital, Girona, Spain.
Miriam SabatGastroenterology Unit, Hospital Santa Caterina, Salt, Girona, Spain.
Santiago López-BenHepato-biliary and Pancreatic Surgery Unit, Dr. Josep Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
Rafael de LlorensDepartment of Biology, University of Girona, Girona, Spain.
Rosa Núria AleixandreClinic Laboratory, Dr. Josep Trueta University Hospital, Girona, Spain.
Rosa PeracaulaDepartment of Biology, University of Girona, Girona, Spain.
Hospital Universitari de Girona Doctor Josep Trueta · ESUniversity of Girona · ESInstitut d'Investigació Biomèdica de Girona · ESHospital Santa Caterina · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is still no reliable biomarker for the diagnosis of pancreatic adenocarcinoma. Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker only recommended for pancreatic adenocarcinoma follow-up. One of the clinical problems lies in distinguishing between this cancer and other benign pancreatic diseases such as chronic pancreatitis. In this study we will assess the value of panels of serum molecules related to pancreatic cancer physiopathology to determine whether alone or in combination could help to discriminate between these two pathologies.

methodsCA 19-9, carcinoembryonic antigen (CEA), C-reactive protein, albumin, insulin growth factor-1 (IGF-1) and IGF binding protein-3 were measured using routine clinical analyzers in a cohort of 47 pancreatic adenocarcinoma, 20 chronic pancreatitis and 15 healthy controls.

resultsThe combination of CA 19-9, IGF-1 and albumin resulted in a combined area under the curve (AUC) of 0.959 with 93.6% sensitivity and 95% specificity, much higher than CA 19-9 alone. An algorithm was defined to classify the patients as chronic pancreatitis or pancreatic cancer with the above specificity and sensitivity. In an independent validation group of 20 pancreatic adenocarcinoma and 13 chronic pancreatitis patients, the combination of the four molecules classified correctly all pancreatic adenocarcinoma and 12 out of 13 chronic pancreatitis patients.

conclusionsAlthough this panel of markers should be validated in larger cohorts, the high sensitivity and specificity values and the convenience to measure these parameters in clinical laboratories shows great promise for improving pancreatic adenocarcinoma diagnosis.

Indexed as

AgedArea Under CurveBilirubinBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenCarcinoma, Pancreatic DuctalC-Reactive ProteinDiagnosis, DifferentialDiagnostic Tests, RoutineFemaleHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IJaundice, ObstructiveMaleBilirubinBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenC-Reactive ProteinIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor ISerum Albumin

Identifiers

PMID26808421
PMCPMC4726554
OpenAlexW2253230571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.